BRPI0415850A - composição de dna estabilizado para o revestimento de micro projeções - Google Patents

composição de dna estabilizado para o revestimento de micro projeções

Info

Publication number
BRPI0415850A
BRPI0415850A BRPI0415850-4A BRPI0415850A BRPI0415850A BR PI0415850 A BRPI0415850 A BR PI0415850A BR PI0415850 A BRPI0415850 A BR PI0415850A BR PI0415850 A BRPI0415850 A BR PI0415850A
Authority
BR
Brazil
Prior art keywords
dna composition
micro projection
stabilized
projection coating
stabilized dna
Prior art date
Application number
BRPI0415850-4A
Other languages
English (en)
Inventor
Michel J N Cormier
Georg Widera
Ameri Mahmoud
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0415850A publication Critical patent/BRPI0415850A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO DE DNA ESTABILIZADO PARA O REVESTIMENTO DE MICRO PROJEçõES". A presente invenção refere-se a um método e composições para a estabilização de ácidos nucléicos secos com carboidratos, tais como açucares de não-redução, polissacarídios e açucares de redução. De preferência, os ácidos nuclêicos estabilizados são revestidos sobre um elemento de microprojeção para um suprimento transdérmico. A invenção ainda proporciona composições e métodos que envolvem o uso de inibidores de DNase para a estabilização do ácido nucléico seco suprido diretamente dentro dos tecidos do corpo.
BRPI0415850-4A 2003-10-23 2004-10-21 composição de dna estabilizado para o revestimento de micro projeções BRPI0415850A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51453303P 2003-10-23 2003-10-23
PCT/US2004/034935 WO2005042702A2 (en) 2003-10-23 2004-10-21 Compositions of stabilized dna for coating microprojections

Publications (1)

Publication Number Publication Date
BRPI0415850A true BRPI0415850A (pt) 2007-01-02

Family

ID=34549340

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415850-4A BRPI0415850A (pt) 2003-10-23 2004-10-21 composição de dna estabilizado para o revestimento de micro projeções

Country Status (11)

Country Link
US (1) US20050090009A1 (pt)
EP (1) EP1678293A2 (pt)
JP (1) JP2007519613A (pt)
KR (1) KR20070011236A (pt)
CN (1) CN101415443A (pt)
AR (1) AR046690A1 (pt)
AU (1) AU2004286232A1 (pt)
BR (1) BRPI0415850A (pt)
CA (1) CA2542874A1 (pt)
TW (1) TW200528152A (pt)
WO (1) WO2005042702A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
WO2005113147A2 (en) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
WO2007061781A1 (en) * 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US8097419B2 (en) * 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
AU2008343745B2 (en) * 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2011080160A1 (en) * 2009-12-29 2011-07-07 Whatman Inc Improvements to nucleic acid elution
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
CN103611214A (zh) * 2013-12-03 2014-03-05 上海交通大学 针药微系统及其制备方法
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
JP7293244B2 (ja) * 2017-10-19 2023-06-19 ストレック， インコーポレイテッド 溶血、凝固調節および細胞外小胞の安定化のための組成物
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
CA3171097A1 (en) * 2020-04-14 2021-10-21 Federico Carlos Arejola Gaeta Products and methods for detection of viral nucleic acid
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136314A (en) * 1960-08-01 1964-06-09 Kravitz Harvey Vaccinating devices
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
OA05448A (fr) * 1975-10-16 1981-03-31 Manufrance Manufacture Francai Dispositif vaccinateur multipénétrant.
FR2474856A1 (fr) * 1980-01-31 1981-08-07 Merieux Inst Dispositif scarificateur
US5164406A (en) * 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
JPH04261119A (ja) * 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
CA2309955A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6918901B1 (en) * 1997-12-10 2005-07-19 Felix Theeuwes Device and method for enhancing transdermal agent flux
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE69921489T2 (de) * 1998-08-31 2005-10-27 Johnson & Johnson Consumer Companies, Inc. Elektrotransportvorrichtung mit klingen
CA2389613A1 (en) * 1999-11-19 2001-05-25 Zycos Inc. Continuous-flow method for preparing microparticles
US6749575B2 (en) * 2001-08-20 2004-06-15 Alza Corporation Method for transdermal nucleic acid sampling
RU2272618C2 (ru) * 2000-09-08 2006-03-27 Алза Корпорейшн Способы ингибирования уменьшения трансдермального движения лекарственного средства посредством ингибирования закрытия путей
ES2317940T3 (es) * 2000-10-13 2009-05-01 Alza Corporation Dispositivo de retencion para un elemento de microsalientes para aplicador de impactos.
EP1341442B1 (en) * 2000-10-13 2005-06-29 Alza Corporation Microblade array impact applicator
CA2427381A1 (en) * 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
CA2435287A1 (en) * 2001-01-17 2002-07-25 Zycos Inc. Nucleic acid delivery formulations
US6855372B2 (en) * 2001-03-16 2005-02-15 Alza Corporation Method and apparatus for coating skin piercing microprojections
US20020193729A1 (en) * 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
NZ529029A (en) * 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating
WO2003000236A1 (en) * 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
US20030199810A1 (en) * 2001-11-30 2003-10-23 Trautman Joseph Creagan Methods and apparatuses for forming microprojection arrays
US20030181936A1 (en) * 2001-12-20 2003-09-25 Trautman Joseph C. Skin-piercing microprojections having piercing depth control
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
AR040302A1 (es) * 2002-06-28 2005-03-23 Alza Corp Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
WO2004030743A2 (en) * 2002-09-30 2004-04-15 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CA2530531A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
AU2004285481A1 (en) * 2003-10-24 2005-05-12 Alza Corporation Apparatus and method for enhancing transdermal drug delivery
JP2007535337A (ja) * 2003-10-28 2007-12-06 アルザ・コーポレーシヨン 被覆された微小突起による治療用ペプチドおよびタンパクのポリマー接合体の送達
CA2546280A1 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery

Also Published As

Publication number Publication date
CN101415443A (zh) 2009-04-22
JP2007519613A (ja) 2007-07-19
WO2005042702A3 (en) 2009-03-26
WO2005042702A2 (en) 2005-05-12
EP1678293A2 (en) 2006-07-12
CA2542874A1 (en) 2005-05-12
KR20070011236A (ko) 2007-01-24
AU2004286232A1 (en) 2005-05-12
US20050090009A1 (en) 2005-04-28
AR046690A1 (es) 2005-12-21
TW200528152A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
WO2005042702A3 (en) Compositions of stabilized dna for coating microprojections
NO20071048L (no) Amidoforbindelser og deres anvendelse som farmasoytika
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
PE20120668A1 (es) Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa
BRPI0911681B8 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
PL363039A1 (pl) Kompozycja kosmetyczna
BRPI0412527A (pt) composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto.
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
BR0315580A (pt) Derivados de metileno uréia
BRPI0609278B8 (pt) método para preparar uma composição farmacêutica e composição farmacêutica
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
NO20055977L (no) Nye benzimidazolderivater
ATE531769T1 (de) Verwendung von estern als koaleszenzmittel
MX2020011339A (es) Polímero catiónico y uso para suministro de biomolecúla.
AR059320A1 (es) Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico
BR112022001054A2 (pt) Inibidores enzimáticos
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.